论文部分内容阅读
目的利拉鲁肽作为新型降糖药,可有效改善胰岛β细胞功能,本研究探讨利拉鲁肽对2型糖尿病(T2DM)患者脂联素(APN)水平及颈动脉粥样硬化的影响。方法选择T2DM患者68例为病例组,同期选择健康者60例为健康组,病例组给予利拉鲁肽治疗,连续治疗12周,治疗结束前后比较两组APN、体质量指数(BMI)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、甘油三酯(TG)、糖化血红蛋白(HbAlc)、白细胞介素6(IL-6)、超敏C反应蛋白(hs-CRP)及颈动脉内膜中层厚度(IMT)等指标。结果治疗前,两组TC、TG比较,差异无统计学意义(均P>0.05);病例组APN低于健康组,BMI、LDL-C、HbAlc、IL-6、hs-CRP及IMT均高于健康组,差异有统计学意义(P<0.05)。治疗后病例组TC、TG与治疗前比较差异无统计学意义(均P>0.05),APN升高,IMT、BMI等指标均下降(P<0.05);但病例组APN仍低于健康组,BMI、LDL-C、HbAlc、IL-6、hs-CRP及IMT仍高于健康组,差异有统计学意义(均P<0.05)。结论利拉鲁肽可上调T2DM患者APN水平,抑制颈总动脉粥样硬化的发生。
Objective Liraglutide as a new hypoglycemic agent can effectively improve the function of pancreatic β cells. This study was to investigate the effect of liraglutide on adiponectin (APN) and carotid atherosclerosis in type 2 diabetes mellitus (T2DM). Methods Sixty-six patients with T2DM were selected as the case group, 60 healthy subjects were selected as healthy group, and the patients were treated with liraglutide for 12 weeks. Before and after treatment, APN, body mass index (BMI), low body mass index (LDL-C), total cholesterol (TC), triglyceride (TG), HbAlc, IL-6 and hs-CRP Carotid artery intima-media thickness (IMT) and other indicators. Results Before treatment, there was no significant difference in TC and TG between the two groups (all P> 0.05). The APN in the case group was lower than that in the healthy group, the levels of BMI, LDL-C, HbAlc, IL-6, hs-CRP and IMT In the healthy group, the difference was statistically significant (P <0.05). There was no significant difference in TC and TG between the two groups after treatment (P> 0.05), APN, IMT and BMI (P <0.05), but the APN in case group was still lower than that in healthy group BMI, LDL-C, HbAlc, IL-6, hs-CRP and IMT were still higher than those in healthy group (all P <0.05). Conclusion Liraglutide can up-regulate APN level in T2DM patients and inhibit the occurrence of common carotid artery atherosclerosis.